Kullanma Kılavuzu

Transkript

Kullanma Kılavuzu
KAPVORM
PMS ZWART
à 100 %
45685-1
DIRECTIONS FOR USE:
FOR INTRAOCULAR USE. FOR SINGLE USE ONLY.
The syringe assembly is designed only for the injection of the PROVISC® Ophthalmic Viscosurgical Device it
contains. Use of the syringe assembly for aspiration is not advised.
Refrigerated PROVISC® OVD should be allowed to attain room temperature prior to use (approximately 20-40
minutes depending on quantity).
BASE OF SYRINGE
GREEN PLUNGER ROD
SYRINGE TIP
®
TIP CAP
GREEN
END CAP
RUBBER PLUNGER
Oftalmik Viskocerrahi Cihaz›
1. PEEL LID FROM BLISTER PACK UNDER ASEPTIC CONDITIONS.
2. REMOVE RUBBER TIP CAP FROM SYRINGE TIP (CAP IS ON TIGHTLY).
TANIMI VE ‹ÇER‹⁄‹
PROVISC® Oftalmik Viskocerrahi Cihaz›, fizyolojik sodyum klorür fosfat tamponunda çözündürülmüfl steril, apirojen, yüksek
moleküler a¤›rl›kl›, non-enflamatuvar, yüksek derecede saflaflt›r›lm›fl sodyum hiyaluronat fraksiyonudur. PROVISC® OVC en az
bir 25,000 mPa.s (kopma oran› 1 sn-1, 25°C) vizkositede formüle edilmifltir.
STERILE IRRIGATING
SOLUTION FILLED HUB
BSS® STERILE
IRRIGATING SOLUTION
CANNULA FILLING HUB
OF PROVISC® OVD
CANNULA
COLORLESS
CARTRIDGE
3. INJECT STERILE IRRIGATING SOLUTION INTO THE CANNULA
HUB AND FILL IT TO THE TOP.
PROVISC Reolojik Profili
®
FULL-SIZE
DETAIL
1000
100
4. EXPRESS THE AIR FROM THE TIP OF THE SYRINGE BY
HOLDING THE SYRINGE BARREL WITH ONE HAND WHILE
GENTLY DEPRESSING THE PLUNGER ROD WITH THE OTHER.
BE CAREFUL NOT TO EXPRESS VISCOSURGICAL DEVICE
ONTO THE OUTSIDE OF THE SYRINGE TIP.
Viskozite (Pa.s)
GREEN CAP
(Sodyum Hiyaluronat)
10
1
0.1
0.01
1e-4
CANNULA (WITH COLORLESS PLASTIC CARTRIDGE STILL IN PLACE)
1e-3
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
Kopma oranı (s-1)
5. THREAD THE CANNULA ONTO THE SYRINGE SLEEVE IN A CONTINUOUS MOTION BY USING THE CARTRIDGE AS A WRENCH. TWIST
UNTIL THE CANNULA HUB HAS TRAVELED THE FULL LENGTH OF THE THREADS AND IS FIRMLY SEATED. USE ONLY THE CANNULA
PROVIDED.
6. VISUALLY INSPECT THAT THE CANNULA THREADS HAVE TRAVELED THE FULL LENGTH OF THE SYRINGE SLEEVE THREADS.
7. REMOVE PLASTIC CARTRIDGE FROM THE CANNULA IN A STRAIGHT MOTION, BEING SURE NOT TO TWIST OR UNSCREW THE CANNULA
WHILE REMOVING THE CARTRIDGE.
CANNULA
PROVISC® OVC’in her ml’sinde aktif 10.0 mg sodyum hiyaluronat; 2.0 mg disodyum fosfat, anhidroz; 0.45 mg sodyum dihidrojen
fosfat; monohidrat; 7.5 mg sodyum klorür; pH de¤erini ayarlamak için hidroklorik asit ve/veya sodyum hidroksit ve enjeksiyon
için su bulunmaktad›r. PROVISC® OVC içinde kullan›lan sodyum hiyaluronat bakteriyel fermantasyondan türemifltir ve 2,500,000
Dalton ortalama molekül a¤›rl›¤›na sahiptir. PROVISC® OVC’in ozmolalitesi 310 ± 50 mOsm/kg; pH’› 7.2 ± 0.4’tür.
ÖNER‹LEN KULLANIM YER‹
PROVISC® OVC, katarakt ekstraksiyonu ve göz içi lens (IOL) implantasyonu s›ras›nda ön segmentte bir göz cerrahisi yard›mc›s›
olarak kullan›lmal›d›r.
Oftalmik visko-elastikler, ön segment cerrahisi s›ras›nda derin bir ön kamaran›n korunmas›n› sa¤layarak kornea endoteli ve civar
göz dokular›n›n daha az travmatize olmas›n› sa¤lamaktad›r. Bu malzemeler vitröz yüzeyin geri itilmesine yard›mc› olmakta ve
ameliyat s›ras›nda düz bir kamara oluflmas›n› önlemektedir.
KULLANILMAMASI GEREKEN DURUMLAR
fiu an itibariyle önerildi¤i flekilde kullan›lmas› kofluluyla PROVISC® OVC kullan›m›na ba¤l› bilinen bir kontrendikasyon mevcut
de¤ildir; bu malzemede bulunan unsurlardan herhangi birine karfl› afl›r› duyarl›l›¤› olan hastalarda dikkat edilmelidir (Bkz. Önlemler
Bölümü).
UYARI
Kullan›m k›lavuzunda verilen talimatlar›n tamam›n› uygulamamas› veya di¤er bir kanül kullan›m› kanül ayr›lmas›na ya da
ciddi bir yaralama olas›l›¤›na neden olabilir.
GREEN CANNULA
LOCKING RING
8. HOLD THE SYRINGE UPRIGHT.
SLIP THE CANNULA LOCKING
RING OVER THE CANNULA
ALLOWING THE DISTAL TIP OF
THE CANNULA TO PASS
THROUGH THE SMALL HOLE IN
THE CANNULA LOCKING RING.
UYARILAR/ÖNLEMLER
(a) Cerrahi giriflim s›ras›nda ön segment cerrahisi kurallar›na uyulmal›d›r.
(b) Sodyum hiyaluronat ürünleriyle ameliyat sonras›nda göz içi bas›nçta art›fl olabildi¤i rapor edilmifltir. G‹B dikkatli bir flekilde
izlenmeli ve önemli bir art›fl›n olmas› halinde uygun tedavi bafllat›lmal›d›r.
(c) Ön kamaray› kapasitesinin üzerinde doldurmay›n›z. PROVISC® OVC’in ameliyat›n sonunda irigasyon ve/veya aspirasyon
yoluyla uzaklaflt›r›lmas› tavsiye edilmektedir. Bu amaç için fl›r›nga birlefltirilmesi önerilmemektedir.
(d) PROVISC® OVC içinde kullan›lan sodyum hiyaluronat patentli bir saflaflt›rma ifllemiyle mikrobik fermantasyonla elde
edilmektedir. Bu materyali proteinden ar›nd›rmak için önlemler al›nm›fl ve ürün alerjenik yan›t yönünden hayvanlarda
denenmifl olmakla birlikte bu cihaz duyarl› kiflilerde kullan›ld›¤›nda alerjik yan›tlar›n oluflmas›na neden olabilir.
(e) Yukar›da hususlar›n yan› s›ra afla¤›daki önlemlerin de al›nmas› gerekmektedir:
– Kanülleri birden fazla sefer kullanmay›n›z.
– Malzemeyi ancak berraksa kullan›n›z.
– Hava kabarc›¤› kalmamas›na dikkat ediniz.
– Sadece ambalaj zarar görmemiflse kullan›n›z.
9. SECURE THE CANNULA BY
ROTATING THE CANNULA
LOCKING RING CLOCKWISE
UNTIL IT STOPS AGAINST THE
CANNULA HUB.
ADVERS ETK‹LER
(a) PROVISC® Oftalmik Viskocerrahi Cihaz› göz cerrahisi ifllemleri s›ras›nda insan gözüne enjekte edildikten sonra iyi tolere
edilmektedir. Ço¤u viskoelastikte oldu¤u gibi baz› vakalarda geçici bir göz içi bas›nc› oldu¤u rapor edilmifltir.
(b) Oftalmik viskoelastikler kullan›ld›¤›nda, kornea ödemi ve kornea dekompensasyonunun yan› s›ra hipopiyon ve irit benzeri
ameliyat sonras› enflamatuvar reaksiyonlar geliflebildi¤i rapor edilmifltir. Bunlar›n sodyum hiyaluronat (PROVISC ® OVC)
kullan›m›yla olan iliflkisi henüz belirlenmemifltir.
10. PURGE THE REMAINING AIR FROM THE SYSTEM BY HOLDING THE SYRINGE BARREL WITH ONE HAND AND GENTLY DEPRESSING THE
PLUNGER ROD WITH THE OTHER UNTIL PROVISC® OVD APPEARS AT THE CANNULA TIP.
SYMBOLS USED ON LABELING
Symbol
Symbol
English
Attention : See Instructions for Use
Do not reuse
English
Sterilized Using Aseptic
Processing Techniques
Sterilized by Ethylene Oxide
Temperature limitation.
Store between 2°- 8°C.
SUNUM fiEKL‹
PROVISC® OVC, 27-gauge, tek kullan›ml›k keskin olmayan uçlu kanül ve kanül kilitleme halkas› ile birlikte 0.4 ml, 0.55 ml
ya da 0.85 ml olarak ambalajlarda tek kullan›ml›k cam fl›r›ngalarda sunulan steril
, apirojen, tek kullan›ml›k
bir
oftalmik viskocerrahi cihazd›r (fizyolojik sodyum klorür fosfat tamponunda çözündürülmüfl 10 mg/ml sodyum hiyaluronat).
Does not contain dry natural
rubber or natural rubber latex
PROVISC® OVC fl›r›ngalar› aseptik olarak doldurulmufl ve blister ambalajlarda paketlenmifltir. fi›r›ngalar›n d›fl k›s›mlar› etilen
oksit yöntemiyle sterilize edilmifltir
.
Use by
Batch Code
21
PAP
© 2007, 2009, 2012 Novartis
Recyclable incorrugated
cardboard
ÇEVKO Green Dot
Manufacturer
Do not use if sterile barrier is
breached.
Distributed by: ALCON LABORATUVARLARI T‹C. A.fi.
Kavac›k Ticaret Merkezi, Rüzgarl›bahçe Mah. Kavak Sok. No:18 B-Blok Kat 1, 34805 Beykoz/STANBUL
Manufacturer: Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, Texas, USA 76134-2099
Produced by: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, Belgium
Authorized EU Representative: Alcon Laboratories (UK) Ltd.
Boundary Way, Hemel Hempstead, Hertfordshire, HP2 7UD, United Kingdom
Dondurulmufl PROVISC® OVC'i kullan›lmadan önce oda s›cakl›¤›na gelmesini bekleyiniz (miktara göre 20-40 dakika).
– Buzdolab›nda saklay›n›z (2° – 8°C, 36° – 46°F).
– Dondurmay›n›z.
– Ifl›k almayacak yerlerde muhafaza ediniz.
Eur. Pat. No. 0 980 276
BELGIUM 45685-1
Provisc IBC 0,40 / 0,55 / 0,85 ml
CE
recto-verso
TR
AANTAL KLEUREN : 1
VC / 14.06.2012
Approval
280 x 335 / 140 x 44 mm
Local
Ready for sending:
Graphics
BESOP-00326
V4
UYGULAMALARI
Katarakt Cerrahisi - IOL ‹mplantasyonu
Ön kamaraya yeterli miktarda PROVISC® Oftalmik Viskocerrahi Cihaz’›n yavafl ve dikkatli bir flekilde enjekte edilmesi için bir
kanül kullan›lmaktad›r. Enjeksiyon kamaraya, kristalin lens ç›kar›lmadan önce ya da sonra yap›labilir.
PROVISC® OVC ayn› zamanda implantasyon cerrahisinden önce göz içi lensin yan› s›ra cerrahi aletlerinin kaplanmas›nda da
kullan›labilir. Cerrahi manipülasyon s›ras›nda yitirilen s›v›y› telafi etmek için cerrahi s›ras›nda enjekte edilebilir. (bkz. Önlemler
Bölümü).
Affiliates
as is.
new proof.
The undersigned:
confirms that this proof contains an accurate translation of the English Corporate
Standard text, and is in compliance with the registered information and the legal
rules. Please also carefully check: local barcodes if any, formula, components if
mentionned, shelflife if mentionned, storage conditions and trademarks.
This proof is approved
Signature and date:
as is.
as is, waiting for M.O.H. approval.
(do not order component yet)
Customer requests
new proof.
Local
Final release:
Graphics
as is.
new proof.
PMS ZWART
à 100 %
KAPVORM
KULLANIM TAL‹MATLARI:
GÖZ ‹Ç‹ KULLANIMINA YÖNEL‹KT‹R. SADECE TEK KULLANIMLIKTIR.
fi›r›nga düzene¤i sadece PROVISC® Oftalmik Viskocerrahi Cihaz›n›n enjekte edilmesi için tasarlanm›flt›r.
fi›r›nga düzene¤inin aspirasyon için kullan›lmas› tavsiye edilmemektedir. Dondurulmufl PROVISC® OVC
kullan›lmadan önce oda s›cakl›¤›na gelmesi beklenmelidir (miktara ba¤l› olarak yaklafl›k 20-40 dakika).
®
Ophthalmic Viscosurgical Device
(sodium hyaluronate)
fiIRINGA TABANI
YEfi‹L P‹STON M‹L‹
fiIRINGA UCU
DESCRIPTION
PROVISC® Ophthalmic Viscosurgical Device is a sterile, non-pyrogenic, high molecular weight, non-inflammatory highly
purified fraction of sodium hyaluronate, dissolved in physiological sodium chloride phosphate buffer. PROVISC® OVD is
formulated to a viscosity of at least 25,000 mPa.s (at shear rate of 1 sec-1, 25°C).
YEfi‹L UÇ
KAPA⁄I
UÇ KAPA⁄I
KAUÇUK P‹STON
1. BL‹STER AMBALAJIN KAPA⁄INI ASEPT‹K KOfiULLAR ALTINDA AÇINIZ.
2. fiIRINGA UCUNDAN KAUÇUK KAPA⁄I ÇIKARTINIZ. (KAPAK SIKICA KAPALIDIR).
PROVISC Rheological Profile
®
1000
100
YEfi‹L KAPAK
PROVISC® OVC
KANÜLÜNÜN BSS®
STER‹L ‹RR‹GASYON
SOLÜSYONU KANÜL
DOLUM KAPA⁄I
RENKS‹Z
KARTUfi
Viscosity (Pa.s)
STER‹L ‹RR‹GASYON
SOLÜSYONU DOLUM
KAPA⁄I
TAM BOY
AYRINTISI
10
1
0.1
0.01
1e-4
1e-3
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
Shear rate (sec-1)
3. KANÜL KAPA⁄INA STER‹L YIKAMA SOLÜSYONU
ENJEKTE ED‹N VE A⁄ZINA KADAR DOLDURUN.
4. fiIRINGA GÖVDES‹N‹ B‹R EL‹N‹ZLE TUTARKEN
D‹⁄ER EL‹N‹ZLE DALMA P‹STONUNU YUMUfiAKÇA
BASTIRARAK fiIRINGANIN UCUNDAK‹ HAVAYI
BOfiALTINIZ. fiIRINGA UCUNUN DIfi KISMINA
V‹SKOELAST‹K TAfiIRMAMAYA D‹KKAT ED‹N‹Z.
KANÜL (RENKS‹Z PLAST‹K KARTUfi HALA TAKILIYKEN)
5. KARTUfiU B‹R SOMUN ANAHTARI G‹B‹ KULLANARAK SÜREKL‹ B‹R HAREKETLE KANÜLÜ fiIRINGA KOLUNA V‹DALAYIN.
KANÜL KAPA⁄INI V‹DALARIN SONUNA GELENE VE SIKICA OTURANA KADAR DÖNDÜRÜN. SADECE B‹RL‹KTE VER‹LEN
KANÜLÜ KULLANIN.
6. KANÜLÜN D‹fiLER‹N‹N, fiIRINGA KOLU V‹DA D‹fi‹NE TAMAMEN OTURDU⁄UNDAN EM‹N OLUN.
7. PLAST‹K KARTUfiU KANÜLDEN DÜZ B‹R HAREKETLE ÇIKARTIN VE KARTUfiU ÇIKARTIRKEN KANÜLÜ DÖNDÜRMEMEYE YA DA SÖKMEMEYE ÖZEN GÖSTER‹N.
8. fiIRINGAYI D‹K TUTUN.
KANÜL K‹L‹TLEME
HALKASINI KANÜLÜN
ÜZER‹NE KAYDIRARAK
KANÜLÜN UZAK UCUNUN
KANÜL K‹L‹TLEME
HALKASINDAK‹ KÜÇÜK
DEL‹KTEN GEÇMES‹N‹
SA⁄LAYIN.
9. KANÜL K‹L‹TLEME
HALKASINI SAAT
‹ST‹KAMET‹NDE KANÜL
KAPA⁄INA YASLANANA
DEK DÖNDÜREREK
KANÜLÜ SAB‹TLEY‹N.
10. fiIRINGANIN GÖVDES‹N‹ B‹R EL‹N‹ZLE TUTARKEN D‹⁄ER EL‹N‹ZLE P‹STON M‹L‹NE, KANÜL UCUNDA PROVISC® OVC
GÖRÜNENE DEK YUMUfiAKÇA BASTIRARAK S‹STEMDE KALAN HAVAYI BOfiALTIN.
Sembol
ETIKETLEMEDE KULLANILAN SEMBOLLER
Açiklamasi
Dikkat: Kullan›m talimatlar›na
bak›n›z
Tekrar kullanmay›n›z
Son kullan›m tarihi
Seri No
Geri Kazan›labilir Karton
PAP
Ürün aseptik ifllem teknikleri
kullan›larak sterilize edilmifltir
Primer Ürün etilen oksit
yöntemiyle sterilize edilmifltir.
Is› k›s›tlamas›.
2°C-8°C aras›nda saklay›n›z.
Kuru do¤al kauçuk ya da do¤al
lateks içermez
ÇEVKO Yeflil Nokta
Da¤›t›c› Firma: ALCON LABORATUVARLARI T‹C. A.fi.
Kavac›k Ticaret Merkezi, Rüzgarl›bahçe Mah. Kavak Sok. No:18 B-Blok Kat 1, 34805 Beykoz/STANBUL
‹malatç›: Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, Texas, ABD 76134-2099
Üretim Yeri: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, BELÇIKA
Yetkili AB Temsilcisi: Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead,
Hertfordshire, HP2 7UD, ‹ngiltere
Eur. Pat. No. 0 980 276
ADVERSE REACTIONS
(a) PROVISC® Ophthalmic Viscosurgical Device is tolerated after injection into human eyes during ophthalmic surgical
procedures. As with most viscoelastics, a transient rise in intraocular pressure has been reported in some cases.
(b) Postoperative inflammatory reactions such as hypopyon and iritis have been reported with the use of ophthalmic
viscoelastics, as well as incidents of corneal edema and corneal decompensation. Their relationship to the use of
sodium hyaluronate (PROVISC ® OVD) has not been established.
APPLICATIONS
Cataract Surgery - IOL Implantation
A cannula is used to slowly and carefully inject a sufficient amount of PROVISC® Ophthalmic Viscosurgical Device into
the anterior chamber. The injection may be performed before or after removal of the crystalline lens. PROVISC® OVD may
also be used to coat surgical instruments and the intraocular lens prior to implantation. Additional PROVISC® OVD can be
injected during surgery to replace any PROVISC® OVD lost during surgical manipulation (see Precautions section).
HOW SUPPLIED
, non-pyrogenic, single use
ophthalmic viscosurgical device (sodium hyaluronate,
PROVISC® OVD is a sterile
10 mg/ml, dissolved in physiological sodium chloride phosphate buffer) supplied in disposable glass syringes delivering
0.4 ml, 0.55 ml or 0.85 ml packaged with a sterile 27-gauge, disposable blunt-tip cannula and cannula locking ring.
PROVISC® OVD syringes are aseptically filled and packaged in blister packs. The exterior of the syringe is sterilized by
ethylene oxide.
Refrigerated PROVISC® OVD should be allowed to attain room temperature prior to use (approximately 20-40 minutes
depending on quantity).
– Store in refrigerator (2°– 8°C, 36°– 46°F).
– Protect from freezing.
– Protect from light.
06-2012
should
be deleted.
BS/RA_2012-Sep-11
45685-1
BELGIUM 45685-1
Provisc IBC 0,40 / 0,55 / 0,85 ml
CE
recto-verso
TR
AANTAL KLEUREN : 1
VC / 14.06.2012
Approval
280 x 335 / 140 x 44 mm
Local
Ready for sending:
Graphics
BESOP-00326
V4
Açiklamasi
E¤er steril koruma zedelenmiflse
kullanmay›n›z.
Üretici
© 2007, 2009, 2012 Novartis
CONTRAINDICATIONS
At present there are no known contraindications to the use of PROVISC® Ophthalmic Viscosurgical Device when used as
recommended; care should be used in patients with hypersensitivity to any components in this material (see Precautions
section).
PRECAUTIONS
(a) Precautions normally associated with anterior segment surgical procedures should be observed.
(b) Postoperative increases in intraocular pressure have been reported with sodium hyaluronate products. The IOP should
be carefully monitored and appropriate therapy instituted if significant increases occur.
(c) Do not overfill the anterior chamber. It is recommended that PROVISC® Ophthalmic Viscosurgical Device be
removed by irrigation and/or aspiration at the close of surgery. Use of the syringe assembly for this purpose
is not advised.
(d) The sodium hyaluronate in PROVISC® OVD is obtained from microbial fermentation by a proprietary purification process.
Although precautions have been taken to make this device protein-free and it has been tested in animals for allergenic
response, this device, used in susceptible persons, may produce allergenic responses.
(e) In addition to the above, the following precautions should be observed:
– Do not reuse cannulas.
– Use only if material is clear.
– Avoid trapping air bubbles.
– Use only if container is undamaged.
YEfi‹L KANÜL
K‹L‹TLEME HALKASI
21
INDICATIONS
PROVISC® Ophthalmic Viscosurgical Device is indicated for use as an ophthalmic surgical aid in the anterior segment
during cataract extraction and intraocular lens (IOL) implantation.
Ophthalmic viscoelastics serve to maintain a deep anterior chamber during anterior segment surgery allowing reduced
trauma to the corneal endothelium and surrounding ocular tissues. They help to push back the vitreous face and prevent
formation of a flat chamber during surgery.
WARNING
Failure to follow all of the assembly instructions in "Directions for Use" or use of an alternate cannula may result
in cannula detachment and the possibility of serious injury.
KANÜL
Sembol
Each ml of PROVISC® OVD contains 10.0 mg sodium hyaluronate ; 2.0 mg disodium phosphate, anhydrous; 0.45 mg
sodium dihydrogen phosphate, monohydrate ; 7.5 mg sodium chloride ; hydrochloric acid and/or sodium hydroxide to adjust
pH and water for injection. The sodium hyaluronate used in PROVISC® OVD is derived from bacterial fermentation and
has an average molecular weight of 2,500,000 Daltons. The osmolality of PROVISC® OVD is 310 ± 50 mOsm/kg; the pH
is 7.2 ± 0.4.
Affiliates
as is.
new proof.
The undersigned:
confirms that this proof contains an accurate translation of the English Corporate
Standard text, and is in compliance with the registered information and the legal
rules. Please also carefully check: local barcodes if any, formula, components if
mentionned, shelflife if mentionned, storage conditions and trademarks.
This proof is approved
Signature and date:
as is.
as is, waiting for M.O.H. approval.
(do not order component yet)
Customer requests
new proof.
Local
Final release:
Graphics
as is.
new proof.

Benzer belgeler